Collegium Pharmaceutical (COLL) Cash & Equivalents (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Cash & Equivalents of $268.6 million for Q1 2026, up 179.28% year-over-year from $96.2 million in Q1 2025, and up 16.17% quarter-over-quarter from $231.3 million in Q4 2025.
Collegium Pharmaceutical (COLL) Cash & Equivalents (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Cash & Equivalents history runs 13 years deep, the most recent figure standing at $268.6 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 179.28% year-over-year to $268.6 million; the TTM figure through Mar 2026 stood at $268.6 million (up 179.28% YoY), while the FY2025 annual figure was $231.3 million, up 227.71% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $268.6 million, up from $231.3 million in the prior quarter.
- The five-year high for Cash & Equivalents was $283.7 million in Q2 2023, with the low at $39.0 million in Q3 2024.
- The 5-year median for Cash & Equivalents is $172.9 million (2024), against an average of $174.3 million.
- The sharpest annual moves came in 2024 and 2025: Cash & Equivalents tumbled 84.93% in 2024, then jumped 285.26% in 2025.
- Collegium Pharmaceutical's Cash & Equivalents stood at $173.7 million in 2022, then jumped by 37.57% to $238.9 million in 2023, then plunged by 70.47% to $70.6 million in 2024, then jumped by 227.71% to $231.3 million in 2025, then gained by 16.17% to $268.6 million in 2026.
- Business Quant data shows COLL's Cash & Equivalents at $268.6 million in Q1 2026, $231.3 million in Q4 2025, and $150.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 164.00 Mn |
| 10 | Collegium Pharmaceutical | 892.67 Mn | 743.35 Mn | 110.29 Mn | 129.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 129.47 Mn |
| Mar 31, 2026 | 268.65 Mn |
| Dec 31, 2025 | 231.25 Mn |
| Sep 30, 2025 | 150.10 Mn |
| Jun 30, 2025 | 117.35 Mn |
| Mar 31, 2025 | 96.19 Mn |
| Dec 31, 2024 | 70.57 Mn |
| Sep 30, 2024 | 38.96 Mn |
| Jun 30, 2024 | 172.89 Mn |
| Mar 31, 2024 | 228.61 Mn |
| Dec 31, 2023 | 238.95 Mn |
| Sep 30, 2023 | 258.53 Mn |
| Jun 30, 2023 | 283.75 Mn |
| Mar 31, 2023 | 269.48 Mn |
| Dec 31, 2022 | 173.69 Mn |
| Sep 30, 2022 | 134.13 Mn |
| Jun 30, 2022 | 122.72 Mn |
| Mar 31, 2022 | 106.70 Mn |
| Dec 31, 2021 | 186.43 Mn |
| Sep 30, 2021 | 193.24 Mn |